Familial hypercholesterolaemia in pregnancy: Australian case series and review.
Mary NangraharyDorothy F GrahamJing PangWendy BarnettGerald F WattsPublished in: The Australian & New Zealand journal of obstetrics & gynaecology (2023)
Pregnancy is associated with prolonged cessation of cholesterol-lowering therapy, a concern with respect to the risk of coronary artery disease in FH. Continuation of statin therapy up to conception and even during pregnancy in patients at higher risk of cardiovascular disease may be justified, especially with increasing evidence supporting the safety of statin therapy during pregnancy. However, more long-term maternal and fetal data are required for the routine use of statins during pregnancy. Guideline-informed models of care covering family planning and pregnancy should be implemented for all women with FH.
Keyphrases
- cardiovascular disease
- coronary artery disease
- pregnancy outcomes
- preterm birth
- healthcare
- cardiovascular events
- low density lipoprotein
- stem cells
- coronary artery bypass grafting
- quality improvement
- percutaneous coronary intervention
- pain management
- metabolic syndrome
- pregnant women
- electronic health record
- bone marrow
- left ventricular
- artificial intelligence
- chronic pain
- data analysis
- atrial fibrillation
- affordable care act
- health insurance